Therapeutic Workshop
Cognition: "CNS Companies to Remember"
Wednesday, February 13, 2008
9:30 AM
West Foyer
Large numbers of aging baby boomers will soon be inching toward old age, and will therefore be increasingly grappling with diminished cognition. This can come in the form of general memory impairment, Alzheimer's, Parkinson's, dementia, among other conditions. Learn about companies that are utilizing novel brain receptors, the familiar gingko biloba, neurological cell death inhibition, and other interesting targets in order to address what will surely be a growing problem in this generation entering their golden years.
Moderators
- Elemer Piros; Senior Biotechnology Analyst, Rodman & Renshaw
Panelists
- J. Donald deBethizy, Ph.D.; Targacept, Inc., President and CEO
- David Hung, M.D.; Medivation, Inc., President and CEO
- John Mordock; President and CEO, Neurologix
- Sid Gilman, M.D., F.R.C.P.; William J. Herdman Professor of Neurology, University of Michigan
Who's Who
Expert: Sid Gilman, MD, FRCP, is the William J. Herdman Distinguished University Professor of Neurology at the University of Michigan and Director of the Michigan Alzheimer's Disease Research Center. He has expertise in neurodegenerative disorders, particularly Alzheimer's disease, Parkinson's disease, and the Parkinson syndromes. Dr. Gilman is also knowledgeable in multiple sclerosis, epilepsy, stroke, pain, and peripheral neuropathy. His research focuses upon brain chemistry changes examined with functional imaging in the dementias, including Alzheimer's disease and Parkinson's disease with dementia. He also uses functional imaging to study disorders of the autonomic nervous system in Parkinson's disease. Dr. Gilman is a consultant to Elan, Wyeth, Johnson & Johnson, and GlaxoSmithKline pharmaceutical companies, and he is Director of the Board of Balboa Biosciences. He is also a consultant for the Peripheral and Central Nervous System Drugs Advisory Committee of the FDA.